Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Boehringer Ingelheim

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Boehringer Ingelheim's 2013 sales performance.

Boehringer Ingelheim GmbH

Sanofi sells European generics to Advent for $2.4bn

Sanofi sells European generics to Advent for $2.4bn

Under Brandicourt, the French group has already divested its animal health business via a 22.8bn asset-swap deal with Boehringer Ingelheim in 2015 that bolstered Sanofi’s consumer health unit.

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal Boehringer Ingelheim has licensed a new checkpoint inhibitor from French biotech OSE Immunotherapeutics in a deal that could be worth more than 1.1bn (around $1.4bn). ... Boehringer has a relatively short heritage in cancer - starting its oncology R&D

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Settlement clears path for Biogen, Samsung’s Humira biosimilar It’s not the end of the matter entirely, as other Humira biosimilars are coming through development, including Boehringer Ingelheim’s Cyltezo which has been approved in the US and

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib line EGFR-mutated NSCLC market with Iressa and Roche's Tarceva (erlotinib), another first-generation drug, as well as newer agents like Boehringer Ingelheim’s Giotrif (afatinib).

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics